Sequencing.com, a top biotech company known for offering the biggest platform for whole genome sequencing and personalized health information, has formed a strategic partnership with PGxAI, a leader in AI-driven pharmacogenomics. This partnership is designed to transform pharmacogenomics by combining advanced genomic data with real-world healthcare uses, with the goal of improving patient results and reducing harmful drug reactions.
Health Technology Insights: Saigon Technology Powers AI Beyond SaaS Limits
As part of this partnership, PGxAI will introduce a full range of pharmacogenomic reports on Sequencing.com’s platform. These reports give personalized information about how a person’s genes affect their reaction to over 730 medications, covering more than 40 genes. This level of coverage is much higher than most competitors, up to five times more, and directly tackles a major healthcare issue — reducing the number of harmful drug reactions, which greatly impact healthcare costs and patient safety.
“Allergic drug reactions cost more than $150 billion extra in healthcare expenses each year in the United States,” said Allan Gobbs, PGxAI’s Executive Chairman and Co-Founder. “Studies show that pharmacogenomics can lower these incidents by around 30 percent. This is a big opportunity to reduce healthcare costs while making treatments safer and more affordable,” he added.
Health Technology Insights: Angle Health and PerfectQuote Launch Real-Time Rate Quotes
Dr. Brandon Colby, Founder and CEO of Sequencing.com, commented, “There is growing demand for pharmacogenomic testing. PGxAI’s strong scientific methods and wide data coverage provide great value to our users and are essential for advancing precision medicine.” Dr. Mike Zack, PGxAI’s CEO and Co-Founder, noted, “More than 99 percent of people have genetic differences that affect how they respond to drugs. Using this information helps doctors customize treatments more safely and effectively, making precision pharmacogenomics a realistic goal in today’s healthcare.”
PGxAI’s reports fit seamlessly with the formats used by clinical genetic testing services, allowing users to easily upload their genetic data and get useful insights based on FDA guidelines and top pharmacogenomics standards. These reports also bring new revenue opportunities for genomic labs. Zack explained, “Our reports are easy for genomic labs to use, offering new income sources and clear benefits for patients.” This partnership marks a major step toward making pharmacogenomic testing more widely available, improving healthcare quality, and lowering unnecessary costs by using the power of AI and genomic science.
Health Technology Insights: Dried Plasma Innovation Addresses Critical Global Need
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
